Iterum Therapeutics Management
Management criteria checks 2/4
Iterum Therapeutics' CEO is Corey Fishman, appointed in Nov 2015, has a tenure of 8.5 years. total yearly compensation is $1.52M, comprised of 40.3% salary and 59.7% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $83.31K. The average tenure of the management team and the board of directors is 3.4 years and 7.8 years respectively.
Key information
Corey Fishman
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 40.3% |
| CEO tenure | 8.5yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.4yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Aug 19
Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03
Aug 12Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate
Jul 11Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
May 06Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Jan 12Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?
Sep 25Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy
Jul 05It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year
Jun 11Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?
May 20Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?
Feb 04This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)
Feb 04Iterum Therapeutics shares slide 13% on raising $10M
Feb 03Iterum Therapeutics rises 39% on RA Capital stake disclosure
Dec 03Iterum Therapeutics files US application for sulopenem in urinary tract infections
Nov 30Iterum Therapeutics EPS beats by $0.45
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$612k | -US$38m |
| Sep 30 2023 | n/a | n/a | -US$31m |
| Jun 30 2023 | n/a | n/a | -US$56m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$1m | US$589k | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$44m |
| Jun 30 2022 | n/a | n/a | -US$11m |
| Mar 31 2022 | n/a | n/a | US$4m |
| Dec 31 2021 | US$11m | US$573k | -US$92m |
| Sep 30 2021 | n/a | n/a | -US$99m |
| Jun 30 2021 | n/a | n/a | -US$115m |
| Mar 31 2021 | n/a | n/a | -US$135m |
| Dec 31 2020 | US$2m | US$561k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$64m |
| Jun 30 2020 | n/a | n/a | -US$84m |
| Mar 31 2020 | n/a | n/a | -US$99m |
| Dec 31 2019 | US$1m | US$551k | -US$103m |
| Sep 30 2019 | n/a | n/a | -US$104m |
| Jun 30 2019 | n/a | n/a | -US$97m |
| Mar 31 2019 | n/a | n/a | -US$85m |
| Dec 31 2018 | US$2m | US$495k | -US$77m |
| Sep 30 2018 | n/a | n/a | -US$62m |
| Jun 30 2018 | n/a | n/a | -US$45m |
| Mar 31 2018 | n/a | n/a | -US$36m |
| Dec 31 2017 | US$755k | US$420k | -US$29m |
Compensation vs Market: Corey's total compensation ($USD1.52M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Corey's compensation has increased whilst the company is unprofitable.
CEO
Corey Fishman (58 yo)
8.5yrs
Tenure
US$1,518,811
Compensation
Mr. Corey N. Fishman serves as Independent Director at BioSpecifics Technologies Corp. since April 9, 2020. Mr. Fishman has been President, Chief Executive Officer and Director at Iterum Therapeutics plc (...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.5yrs | US$1.52m | 0.33% $ 83.3k | |
| Chief Financial Officer | 8.5yrs | US$827.77k | 0.049% $ 12.4k | |
| Strategic Advisor & Director | 3.4yrs | US$115.00k | 0.69% $ 174.0k | |
| Chief Medical Officer | 2.4yrs | US$1.01m | 0.063% $ 15.9k | |
| Senior Vice President of Technical Operations | 3.3yrs | no data | no data | |
| Senior Vice President of Legal Affairs & Secretary | 3.3yrs | no data | no data | |
| Senior VP & Head of Clinical Development | no data | no data | no data |
3.4yrs
Average Tenure
56yo
Average Age
Experienced Management: ITRM's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.5yrs | US$1.52m | 0.33% $ 83.3k | |
| Strategic Advisor & Director | 3.4yrs | US$115.00k | 0.69% $ 174.0k | |
| Independent Chairman of the Board | 8.5yrs | US$88.75k | 0.087% $ 22.0k | |
| Independent Director | 3.2yrs | US$68.50k | 0.11% $ 28.8k | |
| Independent Director | 7.8yrs | US$74.00k | 0.015% $ 3.8k |
7.8yrs
Average Tenure
59yo
Average Age
Experienced Board: ITRM's board of directors are considered experienced (7.8 years average tenure).